Sartorius Stedim Biotech SA
PAR:DIM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
145.35
284.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Sartorius Stedim Biotech SA
Intrinsic Value
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. [ Read More ]
The intrinsic value of one
DIM
stock under the Base Case scenario is
185.22
EUR.
Compared to the current market price of 173.85 EUR,
Sartorius Stedim Biotech SA
is
Undervalued by 6%.
Sartorius Stedim Biotech SA's market capitalization is 16B EUR.
DIM stock price is 173.85 EUR.
DIM stock price (173.85 EUR) is 6% less than its Intrinsic Value (185.22 EUR).
DIM stock price (173.85 EUR) is 35% less than its Relative Value (266.84 EUR). Open Relative Valuation
DIM has upside potential of 46% compared to the average analyst price target.
Open Wall St Estimates
DIM's ROE (Return on Equity) for the past 12 months is positive and is equal to 8%.
DIM's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 5%.
DIM's Revenue has been growing by 8% per year for the last 3 years.
DIM's Revenue is forecast to grow at a rate of 11% per year over the next 3 years.
DIM has positive Net Income for the last twelve months.
DIM's Revenue has dropped by 19% over the past 12 months.
DIM has positive Free Cash Flow for the last twelve months.
DIM's D/E (Debt to Equity) is very low and is equal to 0.8.
DIM's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 21% to 5%.
DIM has positive three-year average ROIC (Return on Invested Capital): 19%. The company is efficient at using invested capital to generate operating income.
DIM has positive Operating Income for the last twelve months.
DIM's long-term assets (8B EUR) exceed its long-term liabilties (5B EUR).
DIM's ROE (Return on Equity) has significantly decreased in the last 3 years from 32% to 8%.
DIM's short-term assets (2B EUR) exceed its short-term liabilties (975m EUR).
DIM has positive Gross Profit for the last twelve months.
DIM has positive Net Debt. This means that the company has more debt (3B EUR) than cash and short-term investments (728m EUR).
DIM has very high three-year average ROE (Return on Equity): 32%. The company is very efficient at transforming stockholders' equity into net income.
DIM's Altman Z-Score is very high and is equal to 4.33.
DIM generates enough operating income (405m EUR) to cover interest payments on its debt (119m EUR).
Valuation Backtest
Sartorius Stedim Biotech SA
Run backtest to discover the historical profit from buying and selling
DIM
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Sartorius Stedim Biotech SA
| Current Assets | 2.1B |
| Cash & Short-Term Investments | 727.7m |
| Receivables | 401.4m |
| Other Current Assets | 948.5m |
| Non-Current Assets | 6.4B |
| Long-Term Investments | 41m |
| PP&E | 1.7B |
| Intangibles | 4.6B |
| Other Non-Current Assets | 64.5m |
| Current Liabilities | 975.4m |
| Accounts Payable | 402.8m |
| Accrued Liabilities | 68.1m |
| Other Current Liabilities | 504.5m |
| Non-Current Liabilities | 3.6B |
| Long-Term Debt | 3.1B |
| Other Non-Current Liabilities | 553.6m |
Earnings Waterfall
Sartorius Stedim Biotech SA
|
Revenue
|
2.7B
EUR
|
|
Cost of Revenue
|
-1.5B
EUR
|
|
Gross Profit
|
1.2B
EUR
|
|
Operating Expenses
|
-762.5m
EUR
|
|
Operating Income
|
404.9m
EUR
|
|
Other Expenses
|
-150.2m
EUR
|
|
Net Income
|
254.7m
EUR
|
Free Cash Flow Analysis
Sartorius Stedim Biotech SA
| EUR | |
| Free Cash Flow | EUR |
DIM Profitability Score
Profitability Due Diligence
Sartorius Stedim Biotech SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Sartorius Stedim Biotech SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
DIM Solvency Score
Solvency Due Diligence
Sartorius Stedim Biotech SA's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Sartorius Stedim Biotech SA's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DIM Price Targets Summary
Sartorius Stedim Biotech SA
According to Wall Street analysts, the average 1-year price target for
DIM
is 253.61 EUR
with a low forecast of 181.8 EUR and a high forecast of 378 EUR.
Click here to dive deeper.
Price Appreciation
DIM Price
Sartorius Stedim Biotech SA
| Average Annual Return | 31.59% |
| Standard Deviation of Annual Returns | 61.82% |
| Max Drawdown | -73% |
| Market Capitalization | 16B EUR |
| Shares Outstanding | 97 283 104 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Sartorius Stedim Biotech SA
Country
Industry
Market Cap
Dividend Yield
Description
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,409 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one
DIM
stock under the Base Case scenario is
185.22
EUR.
Compared to the current market price of 173.85 EUR,
Sartorius Stedim Biotech SA
is
Undervalued by 6%.
You don't have any saved screeners yet
